Your browser doesn't support javascript.
loading
Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin.
Espinet, Elisa; Gu, Zuguang; Imbusch, Charles D; Giese, Nathalia A; Büscher, Magdalena; Safavi, Mariam; Weisenburger, Silke; Klein, Corinna; Vogel, Vanessa; Falcone, Mattia; Insua-Rodríguez, Jacob; Reitberger, Manuel; Thiel, Vera; Kossi, Steffi O; Muckenhuber, Alexander; Sarai, Karnjit; Lee, Alex Y L; Backx, Elyne; Zarei, Soheila; Gaida, Matthias M; Rodríguez-Paredes, Manuel; Donato, Elisa; Yen, Hsi-Yu; Eils, Roland; Schlesner, Matthias; Pfarr, Nicole; Hackert, Thilo; Plass, Christoph; Brors, Benedikt; Steiger, Katja; Weichenhan, Dieter; Arda, H Efsun; Rooman, Ilse; Kopp, Janel L; Strobel, Oliver; Weichert, Wilko; Sprick, Martin R; Trumpp, Andreas.
Afiliação
  • Espinet E; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany. a.trumpp@dkfz.de e.espinet@dkfz.de.
  • Gu Z; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Imbusch CD; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Giese NA; Bioinformatics and Omics Data Analytics, DKFZ, Heidelberg, Germany.
  • Büscher M; Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany.
  • Safavi M; Division of Applied Bioinformatics, DKFZ and NCT, Heidelberg, Germany.
  • Weisenburger S; Department of General and Visceral Surgery, University Hospital Heidelberg, Heidelberg, Germany.
  • Klein C; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Vogel V; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Falcone M; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Insua-Rodríguez J; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Reitberger M; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Thiel V; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Kossi SO; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Muckenhuber A; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Sarai K; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Lee AYL; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Backx E; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Zarei S; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Gaida MM; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Rodríguez-Paredes M; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Donato E; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Yen HY; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Eils R; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Schlesner M; Institute of Pathology, Technical University of Munich, Munich, Germany.
  • Pfarr N; Department of Cellular and Physiological Sciences, Life Science Institute, University of British Columbia, Vancouver, British Columbia, Canada.
  • Hackert T; Department of Cellular and Physiological Sciences, Life Science Institute, University of British Columbia, Vancouver, British Columbia, Canada.
  • Plass C; Laboratory of Molecular and Medical Oncology, Vrije Universiteit Brussel, Brussels, Belgium.
  • Brors B; Department of Cellular and Physiological Sciences, Life Science Institute, University of British Columbia, Vancouver, British Columbia, Canada.
  • Steiger K; Institute of Pathology, University Hospital of Heidelberg, Heidelberg, Germany.
  • Weichenhan D; Institute of Pathology, University Medical Center JGU Mainz, Mainz, Germany.
  • Arda HE; Division of Epigenetics, DKFZ-ZMBH Alliance, DKFZ, Heidelberg, Germany.
  • Rooman I; HI-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH, Heidelberg, Germany.
  • Kopp JL; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Strobel O; Institute of Pathology, Technical University of Munich, Munich, Germany.
  • Weichert W; Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany.
  • Sprick MR; Digital Health Centre, Berlin Institute of Health and Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Trumpp A; Health Data Science Unit, University Hospital and University of Heidelberg, Heidelberg, Germany.
Cancer Discov ; 11(3): 638-659, 2021 03.
Article em En | MEDLINE | ID: mdl-33060108
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive desmoplasia, which challenges the molecular analyses of bulk tumor samples. Here we FACS-purified epithelial cells from human PDAC and normal pancreas and derived their genome-wide transcriptome and DNA methylome landscapes. Clustering based on DNA methylation revealed two distinct PDAC groups displaying different methylation patterns at regions encoding repeat elements. Methylationlow tumors are characterized by higher expression of endogenous retroviral transcripts and double-stranded RNA sensors, which lead to a cell-intrinsic activation of an interferon signature (IFNsign). This results in a protumorigenic microenvironment and poor patient outcome. Methylationlow/IFNsignhigh and Methylationhigh/IFNsignlow PDAC cells preserve lineage traits, respective of normal ductal or acinar pancreatic cells. Moreover, ductal-derived Kras G12D/Trp53 -/- mouse PDACs show higher expression of IFNsign compared with acinar-derived counterparts. Collectively, our data point to two different origins and etiologies of human PDACs, with the aggressive Methylationlow/IFNsignhigh subtype potentially targetable by agents blocking intrinsic IFN signaling.

SIGNIFICANCE:

The mutational landscapes of PDAC alone cannot explain the observed interpatient heterogeneity. We identified two PDAC subtypes characterized by differential DNA methylation, preserving traits from normal ductal/acinar cells associated with IFN signaling. Our work suggests that epigenetic traits and the cell of origin contribute to PDAC heterogeneity.This article is highlighted in the In This Issue feature, p. 521.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Sequências Repetitivas de Ácido Nucleico / Interferons / Metilação de DNA / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Sequências Repetitivas de Ácido Nucleico / Interferons / Metilação de DNA / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article